Related Experiment Video
Updated: Aug 3, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Prognostic impact of cardiohepatic syndrome in patients with ST-segment elevation myocardial infarction
Mustafa A Sungur1, Aylin Sungur2, Ali Karagöz3
1Department of Cardiology, Dr. Siyami Ersek Thoracic & Cardiovascular Surgery Education Research Hospital, Selimiye Mh. Tıbbiye Cd. No: 25 Üsküdar, İstanbul, Turkey.
Insights
Cardiohepatic syndrome (CHS) significantly increases mortality risk in ST-segment elevation myocardial infarction (STEMI) patients. Early CHS evaluation is crucial for risk stratification and improving patient outcomes.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Background:
- Cardiohepatic syndrome (CHS) describes the complex interplay between cardiac and liver function.
- Understanding CHS is vital, particularly in acute cardiovascular events.
Purpose of the Study:
- To assess the impact of CHS on mortality in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention.
- To identify CHS as a prognostic factor in STEMI.
Main Methods:
- A cohort of 1541 STEMI patients who underwent primary percutaneous coronary intervention was analyzed.
- CHS was diagnosed by elevated levels of at least two of three cholestatic liver enzymes: total bilirubin, alkaline phosphatase, and gamma-glutamyl transferase.
Main Results:
- CHS was identified in 144 (9.34%) of the studied STEMI patients.
- Multivariate analysis confirmed CHS as an independent predictor of both in-hospital (OR: 2.48) and long-term mortality (HR: 2.4).
Conclusions:
- The presence of CHS is associated with a poorer prognosis in STEMI patients.
- CHS should be incorporated into the risk stratification protocols for STEMI patients.
Abstract:
Background: Cardiohepatic syndrome (CHS) indicates a bidirectional interaction between the heart and liver. This study was designed to evaluate the impact of CHS on in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention. Materials & methods: 1541 consecutive STEMI patients were examined. CHS was defined as the elevation of at least two of three cholestatic liver enzymes: total bilirubin, alkaline phosphatase and gamma-glutamyl transferase. Results: CHS was present in 144 (9.34%) patients. Multivariate analyses revealed CHS as an independent predictor of in-hospital (odds ratio: 2.48; 95% CI: 1.42-4.34; p = 0.001) and long-term mortality (hazard ratio: 2.4; 95% CI: 1.79-3.22; p < 0.001). Conclusion: The presence of CHS is a predictor of poor prognosis in patients with STEMI and should be evaluated during the risk stratification of these patients.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
Myocarditis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy V: Interprofessional Care